Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia

Molecular Immunology

Volumn 45, Issue 5, 2008, Pages 1525-1529

  Malcikova, J ^a   Smardova, J ^a   Pekova, S ^b   Cejkova, S ^a   Kotaskova, J ^a   Tichy, B ^a   Francova, H ^a   Doubek, M ^a   Brychtova, Y ^a   Janek, D ^c   Pospisilova, S ^a   Mayer, J ^a   Dvorakova, D ^a   Trbusek, M ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

^c Department of Clinical Hematology   (Czech Republic)

Author keywords

Activation induced cytidine deaminase; B cell chronic lymphocytic leukemia; FASAY; Somatic hypermutation; TP53

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; COMPLEMENTARY DNA; GENOMIC DNA;

ADULT; AGED; ARTICLE; ASSAY; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FASAY ANALYSIS; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; POINT MUTATION; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; TP53 GENE; TUMOR SUPPRESSOR GENE;

CYTIDINE DEAMINASE; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; MUTATION; POINT MUTATION; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 37349044622     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.08.017     Document Type: Article

References (23)

1. Dörner T., Foster S.J., Farner N.L., and Lipsky P.E. Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. Eur. J. Immunol. 28 (1998) 3384-3396
2. Epeldegui M., Hung Y.P., McQuay A., Ambinder R.F., and Martinez-Maza O. Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol. Immunol. 44 (2007) 934-942
3. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., Sappino A.P., Limacher I.M., Bron L., Benhattar J., Tada M., Van Meir E.G., Estreicher A., and Iggo R.D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3963-3967
4. Heintel D., Kroemer E., Kienle D., Schwarzinger I., Gleiss A., Schwarzmeier J., Marculescu R., Le T., Mannhalter C., Gaiger A., Stilgenbauer S., Döhner H., Fonatsch C., and Jäger U. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 18 (2004) 756-762
5. Hussain S.P., Schwank J., Staib F., Wang X.W., and Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26 (2007) 2166-2176
6. Kotani A., Okazaki I.M., Muramatsu M., Kinoshita K., Begum N.A., Nakajima T., Saito H., and Honjo T. A target selection of somatic hypermutation is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4506-4511
7. Kou T., Marusawa H., Kinoshita K., Endo Y., Okazaki I., Ueda M., Kodama Y., Haga Y., Ikai H., and Chiba I.T. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int. J. Cancer 120 (2007) 469-476
8. Kröber A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., Döhner H., and Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (2002) 1410-1416
9. Machida K., Cheng K.T., Sung V.M., Shimodaira S., Lindsay K.L., Levine A.M., Lai M.Y., and Lai M.M. Hepatitis C virus induces a mutator phenotype: Enhanced mutations of immunoglobulin and protooncogenes. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4262-4267
10. Matsumoto Y., Marusawa H., Kinoshita K., Endo Y., Kou T., Morisawa T., Azuma T., Okazaki I.M., Honjo T., and Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nature Med. 13 (2007) 470-476
11. Mayorov V.I., Rogozin I.B., Adkison L.R., and Gearhart P.J. DNA polymerase eta contributes to strand bias of mutations of A versus T in immunoglobulin genes. J. Immunol. 174 (2005) 7781-7786
12. Montillo M., Hamblin T., Hallek M., Montserrat E., and Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90 (2005) 391-399
13. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkay Y., and Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 (2000) 553-563
14. Nilsen H., An Q., and Lindahl T. Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice. Oncogene 24 (2005) 3063-3066
15. Petersen-Mahrt S.K., Harris R.S., and Neuberger M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418 (2002) 99-103
16. Rogozin I.B., Pavlov Y.I., Bebenek K., Matsuda T., and Kunkel T.A. Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat. Immunol. 2 (2001) 530-536
17. Sedlacek Z., Kodet R., Seemanova E., Vodvarka P., Wilgenbus P., Mares J., Poustka A., and Goetz P. Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br. J. Cancer 77 (1998) 1034-1039
18. Smardova J., Nemajerova A., Trbusek M., Vagunda V., and Kovarik J. Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol. 22 (2001) 59-66
19. Smardova J., Pavlova S., and Koukalova H. Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol. Oncol. Res. 8 (2002) 245-251
20. Trbusek M., Malcikova J., Smardova J., Kuhrova V., Mentzlova D., Francova H., Bukovska S., Svitakova M., Kuglik P., Linkova V., Doubek M., Brychtova Y., Zacal J., Kujickova J., Pospisilova S., Dvorakova D., Vorlicek J., and Mayer J. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 20 (2006) 1159-1161
21. Waridel F., Estreicher A., Bron L., Flaman J.M., Fontolliet C., Monnier P., Frebourg T., and Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 14 (1997) 163-169
22. Wright B., Reimers J., Schmidt K., Burkala E., Davis N., and Wei P. Mechanisms of genotoxin-induced transcription and hypermutation in p53. Cancer Cell Int. 6 (2006) 27
23. Yavuz A.S., Monson L.N., Yavuz S., Grammer A.C., Longo N., Girschick H.J., and Lipsky P.E. Different patterns of bcl-6 and p53 gene mutations in tonsillar B cells indicate separate mutational machanisms. Mol. Immunol. 39 (2002) 485-493